Testing a stronger rituximab dose schedule for new ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial studies whether a “dose-dense” rituximab schedule can help children and teens with newly diagnosed, high-risk immune thrombocytopenia (ITP). It aims to raise/maintain platelet counts and control bleeding, while carefully checking safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 1 and 21 years old
- Have newly diagnosed ITP with platelets 20 or less (x10^9/L)
- Have at least one high-risk feature (age 10+, significant bleeding, positive ANA, or no recent infection in the last 2 weeks)
- Have had no ITP treatment yet, and no steroid medicine at the equivalent of 0.5 mg/kg prednisone in the last 2 weeks
- Have acceptable kidney and liver lab results based on study blood tests
- Bone marrow test done to rule out cancer in the bone marrow
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
This trial tests whether adding iguratimod (a medicine that helps control immune system activity) to a low dose of rituximab (a targeted therapy for immune cells) works better than low-dose rituximab alone for people with ITP that has not responded to steroid treatment or that comes back after steroids are stopped.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial compares two treatments for adults recently diagnosed with immune thrombocytopenia (ITP) whose platelet count is very low and hasn't improved with standard steroids. The goal is to find a better way to raise platelet counts and reduce bleeding risk.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
Hear when a new Immune Thrombocytopenic Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.